title: [Pharmacological treatment options in frontotemporal dementia].
abstract: In contrast to Alzheimer's disease, there are only few systematic trials for drug therapy of frontotemporal dementia (FTD). Neurochemically, a strong serotonergic deficit is supposed in FTD. This is the rationale for treatment, especially of behavioral abnormalities, with serotonergic antidepressants. However, only paroxetine and trazodone have been studied in trials with class I and II evidence so far. The results of paroxetine are inconsistent; and for trazodone a number of potential side-effects must be considered. Moreover, there is class II evidence for rivastigmine in FTD, even though a cholinergic deficit in this type of dementia is questionable. There are no published data from controlled trials for the use of memantine in FTD so far.
authors.affiliation: Klinik für Psychiatrie und Psychotherapie, Universitätsklinikum des Saarlandes. holger.kessler@uniklink-saarland.de
authors.forename: H
authors.initials: H
authors.lastname: Kessler
authors.forename: T
authors.initials: T
authors.lastname: Supprian
authors.forename: P
authors.initials: P
authors.lastname: Falkai
mesh_terms: D000368:Aged; D000928:Antidepressive Agents / Q000627:therapeutic use; D003704:Dementia / Q000188:drug therapy* / Q000628:therapy; D006801:Humans; D018697:Nootropic Agents / Q000627:therapeutic use
chemical_list: D000928:Antidepressive Agents; D018697:Nootropic Agents